11 research outputs found

    Effect of Bran Particle Size on Gut Microbiota Community Structure and Function

    No full text
    Gut microbiome composition and function are increasingly known to be linked to host health. Many factors control the gut microbiota, including mode of birth, host health status, genetics, and sanitary conditions, but diet has been one of the most-studied factors as a tool to modulate gut microbiota. Dietary fibers that act as prebiotics escape human digestion and reach the colon, where they become available to the microbes as a source of energy. Gut microbes produce various metabolites that are beneficial to the host health. Among those metabolites thought to be most important are the short-chain fatty acids (SCFAs) acetate, propionate, and butyrate. There is high interest in studying prebiotics that increase the production of these SCFAs as they are thought have many health benefits, such as being anti-inflammatory and anti-carcinogenic. Gut commensal preferences for these prebiotics depend on their chemical and physical properties. Other factors like the quantities of prebiotics and in what combinations they are consumed also influence gut microbial populations. There have been many studies conducted to test the effect of chemical differences amongst prebiotics on the gut microbiota, however, research studying the physical properties of dietary fiber and its effect on gut microbes is relatively scarce. To test the hypothesis that physical size of cereal bran particles influences their fermentation by microbiota, we tested different size fractions of wheat and maize bran in in vitro fermentation by fecal microbial communities. Microbes showed size-dependent bran preferences in the case of both wheat and maize bran, both in terms of community structure and metabolites production. For wheat bran, we tested 180-300, 300-500, 500-800, 850-1000 and \u3e1700 m fractions with fecal microbiota from three healthy donors pooled in equal amounts by weight. We saw clear, size-dependent metabolic outcomes (SCFAs production) which were accompanied by divergent microbial community structures as analyzed by 16S rRNA sequencing. We further also linked these responses to size-dependent chemical differences of wheat bran fractions. In the second study with maize bran, we tested 180-250, 250-300, 300-500 and 500-850 m size fractions. Like in the case of wheat bran fractions, maize bran also showed size-dependent microbial community structure and metabolic outputs. Overall, this work demonstrated that bran particle size has potential as a tool for fine-tuning the gut microbiota, which in turn can alter metabolite production and have potential benefits to host health

    Dual-purpose Injectable Doxorubicin Conjugated Alginate Gel Containing Polycaprolactone Microparticles for Anti-Cancer and Anti-Inflammatory Therapy

    No full text
    In situ gel formulations have been widely reported as a carrier for sustained release delivery systems due to certain advantages such as targeted drug delivery, minimal invasiveness and potent therapeutic activity. Herein, in situ gel system for sustained release of doxorubicin and ibuprofen for anti-cancer and anti-inflammatory activity is reported. Doxorubicin-conjugated alginate (dox-alg) gel was prepared using EDC-NHS chemistry and loaded with ibuprofen encapsulated polycaprolactone (PCL) microparticles (dox-alg composite). PCL microparticles were prepared by a solvent evaporation method (size 50 - 100µm). The gel was characterized using SEM, FTIR, XRD and TGA analysis. Dox-alg composite gel showed good syringeability and gel formation properties. Burst release was observed for both drugs within 24 h followed by sustained release till day 21. Doxorubicin released from composite showed considerable cytotoxic effect. Cell uptake was confirmed by confocal microscopy using MDA-MB-231 cells. Anti-inflammatory activity of ibuprofen released from composite gel was compared with the free drug. An injection of dox-alg composite gel in the tissue would fill the void created after tumor removal surgery, prevent the resuscitation of remnant cancerous cells and reduce inflammation. Thus, the dox-alg composite gel could be a potential agent for the dual anti-cancer and anti-inflammatory therapy

    Divergent short-chain fatty acid production and succession of colonic microbiota arise in fermentation of variously-sized wheat bran fractions

    No full text
    Abstract Though the physical structuring of insoluble dietary fiber sources may strongly impact their processing by microbiota in the colon, relatively little mechanistic information exists to explain how these aspects affect microbial fiber fermentation. Here, we hypothesized that wheat bran fractions varying in size would be fermented differently by gut microbiota, which would lead to size-dependent differences in metabolic fate (as short-chain fatty acids; SCFAs) and community structure. To test this hypothesis, we performed an in vitro fermentation assay in which wheat bran particles from a single source were separated by sieving into five size fractions and inoculated with fecal microbiota from three healthy donors. SCFA production, measured by gas chromatography, uncovered size fraction-dependent relationships between total SCFAs produced as well as the molar ratios of acetate, propionate, and butyrate. 16S rRNA sequencing revealed that these size-dependent metabolic outcomes were accompanied by the development of divergent microbial community structures. We further linked these distinct results to subtle, size-dependent differences in chemical composition. These results suggest that physical context can drive differences in microbiota composition and function, that fiber-microbiota interaction studies should consider size as a variable, and that manipulating the size of insoluble fiber-containing particles might be used to control gut microbiome composition and metabolic output

    Improvement in Glucose Regulation Using a Digital Tracker and Continuous Glucose Monitoring in Healthy Adults and Those with Type 2 Diabetes

    No full text
    Introduction While continuous glucose monitoring (CGM) has been shown to decrease both hyper- and hypoglycemia in insulin-treated diabetes, its value in non-insulin-treated type 2 diabetes (T2D) and prediabetes is unclear. Studies examining the reduction in hyperglycemia with the use of CGM in non-insulin-treated T2D are limited. Methods We investigated the potential benefit of CGM combined with a mobile app that links each individual's glucose tracing to meal composition, heart rate, and physical activity in a cohort of 1022 individuals, ranging from nondiabetic to non-insulin-treated T2D, spanning a wide range of demographic, geographic, and socioeconomic characteristics. The primary endpoint was the change in time in range (TIR), defined as 54-140 mg/dL for healthy and prediabetes, and 54-180 mg/dL for T2D, from the beginning to end of a 10-day period of use of the Freestyle Libre CGM. Logged food intake, physical activity, continuous glucose, and heart rate data were captured by a smartphone-based app that continuously provided feedback to participants, overlaying daily glucose patterns with activity and food intake, including macronutrient breakdown, glycemic load (GL), and glycemic index (GI). Results A total of 665 participants meeting eligibility and data requirements were included in the final analysis. Among self-reported nondiabetic participants, CGM identified glucose excursions in the diabetic range among 15% of healthy and 36% of those with prediabetes. In the group as a whole, TIR improved significantly (p < 0.001). Among the 51.4% of participants who improved, TIR increased by an average of 6.4% (p < 0.001). Of those with poor baseline TIR, defined as TIR below comparable A1c thresholds for T2D and prediabetes, 58.3% of T2D and 91.7% of healthy/prediabetes participants improved their TIR by an average of 22.7% and 23.2%, respectively. Predictors of improved response included no prior diagnosis of T2D and lower BMI. Conclusions These results indicate that 10-day use of CGM as a part of multimodal data collection, with synthesis and feedback to participants provided by a mobile health app, can significantly reduce hyperglycemia in non-insulin-treated individuals, including those with early stages of glucose dysregulation
    corecore